These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 15875225)

  • 1. Plasma levels of voriconazole administered via a nasogastric tube to critically ill patients.
    Mohammedi I; Piens MA; Padoin C; Robert D
    Eur J Clin Microbiol Infect Dis; 2005 May; 24(5):358-60. PubMed ID: 15875225
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose voriconazole in a critically ill pediatric patient with neuroblastoma.
    Alffenaar JW; Doedens RA; Groninger E; Kosterink JG
    Pediatr Infect Dis J; 2008 Feb; 27(2):189-90. PubMed ID: 18174859
    [No Abstract]   [Full Text] [Related]  

  • 3. [Update on voriconazole].
    Dtsch Med Wochenschr; 2003 Aug; 128(33):1738. PubMed ID: 12968630
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of oral voriconazole in patients with cystic fibrosis.
    Clifton IJ; Whitaker P; Metcalfe R; Phillip M; Shaw N; Conway SP; Peckham DG
    J Antimicrob Chemother; 2011 Oct; 66(10):2438-40. PubMed ID: 21791443
    [No Abstract]   [Full Text] [Related]  

  • 5. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
    Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
    Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile of voriconazole in a critically ill patient on therapeutic plasma exchange.
    Spriet I; Brüggemann RJ; Annaert P; Meersseman P; Van Wijngaerden E; Lagrou K; Willems L
    Ther Drug Monit; 2013 Feb; 35(1):141-3. PubMed ID: 23296095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of voriconazole in falcons.
    Schmidt V; Demiraj F; Di Somma A; Bailey T; Ungemach FR; Krautwald-Junghanns ME
    Vet Rec; 2007 Aug; 161(8):265-8. PubMed ID: 17720963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.
    Myrianthefs P; Markantonis SL; Evaggelopoulou P; Despotelis S; Evodia E; Panidis D; Baltopoulos G
    Int J Antimicrob Agents; 2010 May; 35(5):468-72. PubMed ID: 20188523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.
    Perkhofer S; Lass-Flörl C
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1393-404. PubMed ID: 19656074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Random plasma concentrations of voriconazole decline over time.
    Mulanovich V; Lewis RE; Raad II; Kontoyiannis DP
    J Infect; 2007 Nov; 55(5):e129-30. PubMed ID: 17804077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of a severe case of fusariomycosis in a beluga whale (Delphinapterus leucas leucas).
    Naples LM; Poll CP; Berzins IK
    J Zoo Wildl Med; 2012 Sep; 43(3):596-602. PubMed ID: 23082525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral voriconazole dose in children: one size does not fit all.
    Goutelle S; Larcher R; Padoin C; Mialou V; Bleyzac N
    Clin Infect Dis; 2010 Oct; 51(7):870; author reply 871. PubMed ID: 20809842
    [No Abstract]   [Full Text] [Related]  

  • 13. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients.
    Troke PF; Hockey HP; Hope WW
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4782-8. PubMed ID: 21768513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic/pharmacodynamic profile of voriconazole.
    Theuretzbacher U; Ihle F; Derendorf H
    Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation.
    Brüggemann RJ; Antonius T; Heijst Av; Hoogerbrugge PM; Burger DM; Warris A
    Ther Drug Monit; 2008 Dec; 30(6):643-6. PubMed ID: 19057370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An alternative approach to determine oral bioavailability of drugs that follow Michaelis-Menten elimination: a case study with voriconazole.
    Verlindo de Araujo B; Farias da Silva C; Costa TD
    Pharmacology; 2010; 86(3):163-7. PubMed ID: 20714206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphobutylether-beta-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis.
    Burkhardt O; Thon S; Burhenne J; Welte T; Kielstein JT
    Int J Antimicrob Agents; 2010 Jul; 36(1):93-4. PubMed ID: 20381320
    [No Abstract]   [Full Text] [Related]  

  • 18. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen.
    Capitano B; Potoski BA; Husain S; Zhang S; Paterson DL; Studer SM; McCurry KR; Venkataramanan R
    Antimicrob Agents Chemother; 2006 May; 50(5):1878-80. PubMed ID: 16641467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
    Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
    Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of single, oral-dose voriconazole in peritoneal dialysis patients.
    Peng LW; Lien YH
    Am J Kidney Dis; 2005 Jan; 45(1):162-6. PubMed ID: 15696456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.